Clinical Trials Search
A Phase III, Multicenter, Randomized,Placebo-Controlled, Double-Blind Study of Atezolizumab (AntiPd-L1 Antibody) as Adjuvant Therapy in Patients with Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy
The purpose of this study is to compare the effects, good or bad, of atezolizumab versus placebo (an inactive substance that looks like atezolizumab) on participants and their renal cell carcinoma (RCC) to find out which is better. In this study, participants will get either atezolizumab or placebo.
To evaluate the efficacy of adjuvant treatment with atezolizumab. Investigator-assessed disease-free survival (DFS), defined as the time from randomization to the first documented DFS event, defined as any of the following: Local recurrence of renal cell carcinoma (RCC). New primary RCC. Distant metastasis of RCC. Death from any cause.